ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Direct Oral Anticoagulants (DOACs) Market Research Report 2026
Published Date: 2026-02-06
|
Report Code: QYRE-Auto-37R18450
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Direct Oral Anticoagulants DOACs Market Research Report 2024
BUY CHAPTERS

Global Direct Oral Anticoagulants (DOACs) Market Research Report 2026

Code: QYRE-Auto-37R18450
Report
2026-02-06
Pages:127
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
Pfizer Inc
Daiichi Sankyo
Janssen Pharmaceuticals
Bayer
Viatris
Boehringer Ingelheim
Accord Healthcare
Sandoz Inc
Teva Pharmaceutical
Mylan NV
Apotex
GlaxoSmithKline PLC

Direct Oral Anticoagulants (DOACs) Market Size

The global Direct Oral Anticoagulants (DOACs) market was valued at US$ 50670 million in 2025 and is anticipated to reach US$ 85640 million by 2032, at a CAGR of 7.9% from 2026 to 2032.

Direct Oral Anticoagulants (DOACs) Market

Direct Oral Anticoagulants (DOACs) Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Direct Oral Anticoagulants (DOACs) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Direct oral anticoagulants (DOACs) are a class of medications used to prevent and treat blood clots by directly inhibiting specific enzymes involved in the clotting process.They include drugs that directly target either Factor Xa (such as rivaroxaban and apixaban) or thrombin (such as dabigatran), effectively reducing the risk of conditions like deep vein thrombosis, pulmonary embolism, and stroke in atrial fibrillation.
The market for Direct Oral Anticoagulants (DOACs) has experienced significant growth over the past decade. Initially introduced as alternatives to traditional anticoagulants like warfarin, DOACs offer advantages such as fixed dosing, fewer dietary restrictions, and minimal need for regular monitoring. The rising incidence of conditions such as atrial fibrillation and venous thromboembolism, coupled with an aging population, has driven increased demand for these medications. Consequently, the market has seen a surge in both prescription volume and the number of available DOACs.
In recent years, competition among pharmaceutical companies has intensified, leading to a broader range of DOAC options and potential price fluctuations. Major players like Bayer, Pfizer, and Bristol-Myers Squibb have continually advanced their products, seeking to differentiate through efficacy, safety profiles, and patient convenience. Additionally, the market has seen innovations such as the development of reversal agents for DOACs, addressing concerns over bleeding risks and enhancing the attractiveness of these drugs to both healthcare providers and patients.
Looking forward, the DOAC market is expected to continue its upward trajectory, driven by ongoing research, expanding indications, and increased global access. Emerging markets, where chronic diseases are rising alongside economic growth, present new opportunities for expansion. However, the market will also face challenges, including regulatory hurdles, potential generic competition, and the need for ongoing clinical trials to further establish long-term safety and efficacy. Overall, the DOAC market remains dynamic, with robust prospects shaped by evolving medical needs and technological advancements.
This report delivers a comprehensive overview of the global Direct Oral Anticoagulants (DOACs) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Direct Oral Anticoagulants (DOACs). The Direct Oral Anticoagulants (DOACs) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Direct Oral Anticoagulants (DOACs) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Direct Oral Anticoagulants (DOACs) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Direct Oral Anticoagulants (DOACs) Market Report

Report Metric Details
Report Name Direct Oral Anticoagulants (DOACs) Market
Accounted market size in 2025 US$ 50670 million
Forecasted market size in 2032 US$ 85640 million
CAGR 7.9%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Oral Factor Xa Inhibitors
  • Direct Thrombin Inhibitors (DTIs)
by Application
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Viatris, Boehringer Ingelheim, Accord Healthcare, Sandoz, Teva Pharmaceutical, Mylan, Apotex, GlaxoSmithKline
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Direct Oral Anticoagulants (DOACs) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Direct Oral Anticoagulants (DOACs) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Direct Oral Anticoagulants (DOACs) Market growing?

Ans: The Direct Oral Anticoagulants (DOACs) Market witnessing a CAGR of 7.9% during the forecast period 2026-2032.

What is the Direct Oral Anticoagulants (DOACs) Market size in 2032?

Ans: The Direct Oral Anticoagulants (DOACs) Market size in 2032 will be US$ 85640 million.

Who are the main players in the Direct Oral Anticoagulants (DOACs) Market report?

Ans: The main players in the Direct Oral Anticoagulants (DOACs) Market are Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Janssen Pharmaceuticals, Bayer, Viatris, Boehringer Ingelheim, Accord Healthcare, Sandoz, Teva Pharmaceutical, Mylan, Apotex, GlaxoSmithKline

What are the Application segmentation covered in the Direct Oral Anticoagulants (DOACs) Market report?

Ans: The Applications covered in the Direct Oral Anticoagulants (DOACs) Market report are Deep Vein Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Other

What are the Type segmentation covered in the Direct Oral Anticoagulants (DOACs) Market report?

Ans: The Types covered in the Direct Oral Anticoagulants (DOACs) Market report are Oral Factor Xa Inhibitors, Direct Thrombin Inhibitors (DTIs)

1 Direct Oral Anticoagulants (DOACs) Market Overview
1.1 Product Definition
1.2 Direct Oral Anticoagulants (DOACs) by Type
1.2.1 Global Direct Oral Anticoagulants (DOACs) Market Value by Type: 2025 vs 2032
1.2.2 Oral Factor Xa Inhibitors
1.2.3 Direct Thrombin Inhibitors (DTIs)
1.3 Direct Oral Anticoagulants (DOACs) by Application
1.3.1 Global Direct Oral Anticoagulants (DOACs) Market Value by Application: 2025 vs 2032
1.3.2 Deep Vein Thrombosis
1.3.3 Pulmonary Embolism
1.3.4 Atrial Fibrillation
1.3.5 Other
1.4 Global Direct Oral Anticoagulants (DOACs) Market Size Estimates and Forecasts
1.4.1 Global Direct Oral Anticoagulants (DOACs) Revenue 2021–2032
1.4.2 Global Direct Oral Anticoagulants (DOACs) Sales 2021–2032
1.4.3 Global Direct Oral Anticoagulants (DOACs) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Direct Oral Anticoagulants (DOACs) Market Competition by Manufacturers
2.1 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Direct Oral Anticoagulants (DOACs) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Direct Oral Anticoagulants (DOACs), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Product Types and Applications
2.7 Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Date of Entry into the Industry
2.8 Global Direct Oral Anticoagulants (DOACs) Market Competitive Situation and Trends
2.8.1 Global Direct Oral Anticoagulants (DOACs) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Direct Oral Anticoagulants (DOACs) Players Market Share by Revenue
2.8.3 Global Direct Oral Anticoagulants (DOACs) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Direct Oral Anticoagulants (DOACs) Market Scenario by Region
3.1 Global Direct Oral Anticoagulants (DOACs) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021–2032
3.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2021–2026
3.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2027–2032
3.3 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021–2032
3.3.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021–2026
3.3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Region: 2027–2032
3.4 North America Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
3.4.1 North America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021–2032)
3.4.3 North America Direct Oral Anticoagulants (DOACs) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
3.5.1 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021–2032)
3.5.3 Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Region
3.6.1 Asia Pacific Direct Oral Anticoagulants (DOACs) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Region (2021–2032)
3.6.3 Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
3.7.1 Latin America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (2021–2032)
3.7.3 Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021–2032)
4.1.1 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021–2026)
4.1.2 Global Direct Oral Anticoagulants (DOACs) Sales by Type (2027–2032)
4.1.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021–2032)
4.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021–2032)
4.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2021–2026)
4.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Type (2027–2032)
4.2.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021–2032)
4.3 Global Direct Oral Anticoagulants (DOACs) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021–2032)
5.1.1 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021–2026)
5.1.2 Global Direct Oral Anticoagulants (DOACs) Sales by Application (2027–2032)
5.1.3 Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021–2032)
5.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021–2032)
5.2.1 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2021–2026)
5.2.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Application (2027–2032)
5.2.3 Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021–2032)
5.3 Global Direct Oral Anticoagulants (DOACs) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Bristol Myers Squibb
6.1.1 Bristol Myers Squibb Company Information
6.1.2 Bristol Myers Squibb Description and Business Overview
6.1.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
6.1.5 Bristol Myers Squibb Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Daiichi Sankyo
6.3.1 Daiichi Sankyo Company Information
6.3.2 Daiichi Sankyo Description and Business Overview
6.3.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
6.3.5 Daiichi Sankyo Recent Developments/Updates
6.4 Janssen Pharmaceuticals
6.4.1 Janssen Pharmaceuticals Company Information
6.4.2 Janssen Pharmaceuticals Description and Business Overview
6.4.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
6.4.5 Janssen Pharmaceuticals Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Company Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 Viatris
6.6.1 Viatris Company Information
6.6.2 Viatris Description and Business Overview
6.6.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
6.6.5 Viatris Recent Developments/Updates
6.7 Boehringer Ingelheim
6.7.1 Boehringer Ingelheim Company Information
6.7.2 Boehringer Ingelheim Description and Business Overview
6.7.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Accord Healthcare
6.8.1 Accord Healthcare Company Information
6.8.2 Accord Healthcare Description and Business Overview
6.8.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
6.8.5 Accord Healthcare Recent Developments/Updates
6.9 Sandoz
6.9.1 Sandoz Company Information
6.9.2 Sandoz Description and Business Overview
6.9.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
6.9.5 Sandoz Recent Developments/Updates
6.10 Teva Pharmaceutical
6.10.1 Teva Pharmaceutical Company Information
6.10.2 Teva Pharmaceutical Description and Business Overview
6.10.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
6.10.5 Teva Pharmaceutical Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Company Information
6.11.2 Mylan Description and Business Overview
6.11.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
6.11.5 Mylan Recent Developments/Updates
6.12 Apotex
6.12.1 Apotex Company Information
6.12.2 Apotex Description and Business Overview
6.12.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
6.12.5 Apotex Recent Developments/Updates
6.13 GlaxoSmithKline
6.13.1 GlaxoSmithKline Company Information
6.13.2 GlaxoSmithKline Description and Business Overview
6.13.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
6.13.5 GlaxoSmithKline Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Direct Oral Anticoagulants (DOACs) Industry Chain Analysis
7.2 Direct Oral Anticoagulants (DOACs) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Direct Oral Anticoagulants (DOACs) Production Mode & Process Analysis
7.4 Direct Oral Anticoagulants (DOACs) Sales and Marketing
7.4.1 Direct Oral Anticoagulants (DOACs) Sales Channels
7.4.2 Direct Oral Anticoagulants (DOACs) Distributors
7.5 Direct Oral Anticoagulants (DOACs) Customer Analysis
8 Direct Oral Anticoagulants (DOACs) Market Dynamics
8.1 Direct Oral Anticoagulants (DOACs) Industry Trends
8.2 Direct Oral Anticoagulants (DOACs) Market Drivers
8.3 Direct Oral Anticoagulants (DOACs) Market Challenges
8.4 Direct Oral Anticoagulants (DOACs) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
Pfizer Inc
Daiichi Sankyo
Janssen Pharmaceuticals
Bayer
Viatris
Boehringer Ingelheim
Accord Healthcare
Sandoz Inc
Teva Pharmaceutical
Mylan NV
Apotex
GlaxoSmithKline PLC
List of Tables
 Table 1. Global Direct Oral Anticoagulants (DOACs) Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Direct Oral Anticoagulants (DOACs) Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Direct Oral Anticoagulants (DOACs) Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Direct Oral Anticoagulants (DOACs) Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Direct Oral Anticoagulants (DOACs) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Direct Oral Anticoagulants (DOACs), Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Product Types and Applications
 Table 12. Global Key Manufacturers of Direct Oral Anticoagulants (DOACs), Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Direct Oral Anticoagulants (DOACs) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Direct Oral Anticoagulants (DOACs) Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Direct Oral Anticoagulants (DOACs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Direct Oral Anticoagulants (DOACs) Sales by Region (K Units), 2021–2026
 Table 18. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021–2026)
 Table 19. Global Direct Oral Anticoagulants (DOACs) Sales by Region (K Units), 2027–2032
 Table 20. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2027–2032)
 Table 21. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021–2026)
 Table 23. Global Direct Oral Anticoagulants (DOACs) Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2027–2032)
 Table 25. North America Direct Oral Anticoagulants (DOACs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2021–2026
 Table 27. North America Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2027–2032
 Table 28. North America Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2021–2026
 Table 32. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2027–2032
 Table 33. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2021–2026
 Table 42. Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2027–2032
 Table 43. Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Type (2021–2026)
 Table 51. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Type (2027–2032)
 Table 52. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2021–2026)
 Table 53. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Type (2027–2032)
 Table 54. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2021–2026)
 Table 57. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Type (2027–2032)
 Table 58. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Application (2021–2026)
 Table 61. Global Direct Oral Anticoagulants (DOACs) Sales (K Units) by Application (2027–2032)
 Table 62. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2021–2026)
 Table 63. Global Direct Oral Anticoagulants (DOACs) Sales Market Share by Application (2027–2032)
 Table 64. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Direct Oral Anticoagulants (DOACs) Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2021–2026)
 Table 67. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Application (2027–2032)
 Table 68. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Application (2027–2032)
 Table 70. Bristol Myers Squibb Company Information
 Table 71. Bristol Myers Squibb Description and Business Overview
 Table 72. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product
 Table 74. Bristol Myers Squibb Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Pfizer Direct Oral Anticoagulants (DOACs) Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. Daiichi Sankyo Company Information
 Table 81. Daiichi Sankyo Description and Business Overview
 Table 82. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product
 Table 84. Daiichi Sankyo Recent Developments/Updates
 Table 85. Janssen Pharmaceuticals Company Information
 Table 86. Janssen Pharmaceuticals Description and Business Overview
 Table 87. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product
 Table 89. Janssen Pharmaceuticals Recent Developments/Updates
 Table 90. Bayer Company Information
 Table 91. Bayer Description and Business Overview
 Table 92. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Bayer Direct Oral Anticoagulants (DOACs) Product
 Table 94. Bayer Recent Developments/Updates
 Table 95. Viatris Company Information
 Table 96. Viatris Description and Business Overview
 Table 97. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Viatris Direct Oral Anticoagulants (DOACs) Product
 Table 99. Viatris Recent Developments/Updates
 Table 100. Boehringer Ingelheim Company Information
 Table 101. Boehringer Ingelheim Description and Business Overview
 Table 102. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product
 Table 104. Boehringer Ingelheim Recent Developments/Updates
 Table 105. Accord Healthcare Company Information
 Table 106. Accord Healthcare Description and Business Overview
 Table 107. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product
 Table 109. Accord Healthcare Recent Developments/Updates
 Table 110. Sandoz Company Information
 Table 111. Sandoz Description and Business Overview
 Table 112. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Sandoz Direct Oral Anticoagulants (DOACs) Product
 Table 114. Sandoz Recent Developments/Updates
 Table 115. Teva Pharmaceutical Company Information
 Table 116. Teva Pharmaceutical Description and Business Overview
 Table 117. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product
 Table 119. Teva Pharmaceutical Recent Developments/Updates
 Table 120. Mylan Company Information
 Table 121. Mylan Description and Business Overview
 Table 122. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Mylan Direct Oral Anticoagulants (DOACs) Product
 Table 124. Mylan Recent Developments/Updates
 Table 125. Apotex Company Information
 Table 126. Apotex Description and Business Overview
 Table 127. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. Apotex Direct Oral Anticoagulants (DOACs) Product
 Table 129. Apotex Recent Developments/Updates
 Table 130. GlaxoSmithKline Company Information
 Table 131. GlaxoSmithKline Description and Business Overview
 Table 132. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product
 Table 134. GlaxoSmithKline Recent Developments/Updates
 Table 135. Key Raw Materials Lists
 Table 136. Raw Materials Key Suppliers Lists
 Table 137. Direct Oral Anticoagulants (DOACs) Distributors List
 Table 138. Direct Oral Anticoagulants (DOACs) Customers List
 Table 139. Direct Oral Anticoagulants (DOACs) Market Trends
 Table 140. Direct Oral Anticoagulants (DOACs) Market Drivers
 Table 141. Direct Oral Anticoagulants (DOACs) Market Challenges
 Table 142. Direct Oral Anticoagulants (DOACs) Market Restraints
 Table 143. Research Programs/Design for This Report
 Table 144. Key Data Information from Secondary Sources
 Table 145. Key Data Information from Primary Sources
 Table 146. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Direct Oral Anticoagulants (DOACs)
 Figure 2. Global Direct Oral Anticoagulants (DOACs) Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Direct Oral Anticoagulants (DOACs) Market Share by Type: 2025 & 2032
 Figure 4. Oral Factor Xa Inhibitors Product Picture
 Figure 5. Direct Thrombin Inhibitors (DTIs) Product Picture
 Figure 6. Global Direct Oral Anticoagulants (DOACs) Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Direct Oral Anticoagulants (DOACs) Market Share by Application: 2025 & 2032
 Figure 8. Deep Vein Thrombosis
 Figure 9. Pulmonary Embolism
 Figure 10. Atrial Fibrillation
 Figure 11. Other
 Figure 12. Global Direct Oral Anticoagulants (DOACs) Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global Direct Oral Anticoagulants (DOACs) Market Size (US$ Million), 2021–2032
 Figure 14. Global Direct Oral Anticoagulants (DOACs) Sales (K Units), 2021–2032
 Figure 15. Global Direct Oral Anticoagulants (DOACs) Average Price (US$/Unit), 2021–2032
 Figure 16. Direct Oral Anticoagulants (DOACs) Report Years Considered
 Figure 17. Direct Oral Anticoagulants (DOACs) Sales Share by Manufacturers in 2025
 Figure 18. Global Direct Oral Anticoagulants (DOACs) Revenue Share by Manufacturers in 2025
 Figure 19. Top 5 and Top 10 Global Direct Oral Anticoagulants (DOACs) Players: Market Share by Revenue in Direct Oral Anticoagulants (DOACs) in 2025
 Figure 20. Direct Oral Anticoagulants (DOACs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 21. Global Direct Oral Anticoagulants (DOACs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 22. North America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021–2032)
 Figure 23. North America Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021–2032)
 Figure 24. United States Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Canada Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 26. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021–2032)
 Figure 27. Europe Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021–2032)
 Figure 28. Germany Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. France Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. U.K. Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Italy Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Russia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Asia Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share by Region (2021–2032)
 Figure 34. Asia Pacific Direct Oral Anticoagulants (DOACs) Revenue Market Share by Region (2021–2032)
 Figure 35. China Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Japan Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. South Korea Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. India Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Australia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. China Taiwan Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Southeast Asia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021–2032)
 Figure 43. Latin America Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021–2032)
 Figure 44. Mexico Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Brazil Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Argentina Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Colombia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021–2032)
 Figure 49. Middle East and Africa Direct Oral Anticoagulants (DOACs) Revenue Market Share by Country (2021–2032)
 Figure 50. Turkey Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Saudi Arabia Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. UAE Direct Oral Anticoagulants (DOACs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Global Sales Market Share of Direct Oral Anticoagulants (DOACs) by Type (2021–2032)
 Figure 54. Global Revenue Market Share of Direct Oral Anticoagulants (DOACs) by Type (2021–2032)
 Figure 55. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Type (2021–2032)
 Figure 56. Global Sales Market Share of Direct Oral Anticoagulants (DOACs) by Application (2021–2032)
 Figure 57. Global Revenue Market Share of Direct Oral Anticoagulants (DOACs) by Application (2021–2032)
 Figure 58. Global Direct Oral Anticoagulants (DOACs) Price (US$/Unit) by Application (2021–2032)
 Figure 59. Direct Oral Anticoagulants (DOACs) Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Oral Factor Xa Inhibitors Market Research Report 2024
Global Direct Oral Anticoagulant Market Insights Forecast to 2030
Global Edoxaban Tosilate Tablets and Generic Drugs Market Research Report 2024
Global Rivaroxaban Drugs Market Research Report 2024
Global Direct Thrombin Inhibitors DTIs Market Research Report 2024
Global Oral Anticoagulants Market Research Report 2024
Global Factor Xa Inhibitors Market Research Report 2024
Global Dabigatran Etexilate Drugs Market Research Report 2024
Global Anticoagulant Medicines Market Research Report 2025
Global Edoxaban API Market Research Report 2024
Anticoagulants Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Rivaroxaban API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Novel Oral Anticoagulants Drugs Market Insights Forecast to 2030
Global Edoxaban Tosilate Orally Disintegrating Tablets Market Research Report 2024
Global FXa Inhibitor Market Research Report 2025
Global Intravenous Anticoagulants Market Research Report 2024
Global Heparin Anticoagulant Market Insights Forecast to 2028
Global Rivaroxaban Tablets Market Research Report 2024
Global Dabigatran Market Insights Forecast to 2030
Global Dabigatran Etexilate Mesylate Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions